Dr. Raymond Comenzo received his medical degree from Boston University School of Medicine. He completed his internship and residency in medicine at Boston City Hospital, followed by his fellowship in hematology/oncology at New England Medical Center. Dr. Comenzo is professor of medicine and pathology at Tufts University School of Medicine and director of the Blood Bank and Stem Cell Processing Laboratory.

Dr. Comenzo is board certified in internal medicine, medical oncology, and hematology. He is on the Scientific Advisory Board, International Myeloma Foundation; Board of Directors, Amyloidosis Foundation; and the Eastern Clinical Oncology Group (ECOG), Myeloma Committee. In addition he holds memberships in the Massachusetts Medical Society, American Society of Hematology (ASH), and the American Association of Blood Banks. Dr. Comenzo is also a reviewer for Transfusion, Journal of Clinical Apheresis, Blood, Journal of Clinical Oncology, New England Journal of Medicine, Leukemia, Cancer Research, and Haematologica. His major research interests include autologous stem cell transplantation for systemic amyloidosis, gene silencing therapy for light-chain myeloma, and the role of proteasome inhibitors in plasma cell diseases.

Faculty Disclosure
Dr. Raymond Comenzo has disclosed that he has received honoraria as a consultant from Millennium Pharmaceuticals, Inc. (A wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) and Takeda Pharmaceutical Company Limited, as well as grant support related to research activities from Millennium, Prothena Corporation plc, Takeda, and Teva Pharmaceuticals.